Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences Inc (ANIX) is a clinical-stage biotechnology company developing cancer immunotherapies and preventive cancer vaccines. The company's news flow centers on clinical trial progress, regulatory milestones, patent developments, and research collaborations advancing its oncology programs.
Investors tracking Anixa can expect news related to clinical trial data releases, particularly results from studies evaluating its chimeric endocrine receptor T-cell therapy for breast and ovarian cancers and its prophylactic breast cancer vaccine. The company announces investigational new drug application submissions, treatment of first patients in clinical studies, and completion of trial enrollment milestones as programs advance through development stages.
Patent-related announcements form another significant category of Anixa news, including notices of patent allowances from the U.S. Patent and Trademark Office, patent issuances in international markets, and expansions of intellectual property protection for both therapeutic technologies and the company's technology patent portfolio. These developments strengthen the company's commercial position and licensing revenue potential.
Research collaboration updates provide insight into partnerships with academic medical centers and cancer research institutions conducting sponsored studies. The company also announces participation in investor conferences and healthcare industry events where management presents corporate updates and interacts with the investment community.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced a Notice of Allowance from the U.S. Patent and Trademark Office regarding its breast cancer vaccine technology. This notice broadens intellectual property protection for the vaccine, which aims to prevent Triple Negative Breast Cancer (TNBC). Developed in collaboration with Cleveland Clinic, the vaccine is currently in Phase 1 clinical trials, with preliminary results expected by year-end. The technology leverages a breast-specific protein, α-lactalbumin, to stimulate immune protection against certain breast tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the publication of a peer-reviewed article in Clinical and Experimental Vaccine Research, detailing preclinical studies on a novel ovarian cancer vaccine technology using AddaVax adjuvant. The study indicates that the vaccine targets the anti-Müllerian hormone receptor 2, potentially preventing ovarian cancer—a challenging malignancy. Anixa's CEO stated that clinical development is ongoing, backed by the National Cancer Institute's PREVENT Program. This technology represents a significant advancement in cancer prevention.
Anixa Biosciences, Inc. (NASDAQ: ANIX) will present a company update at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will cover Anixa's recent achievements, including the initiation of a clinical trial for its CAR-T based ovarian cancer treatment. The on-demand presentation starts at 7:00 a.m. ET on May 24, 2022, and can be accessed through a provided webcast link. A replay will be available for 90 days. Anixa focuses on cancer therapies and infectious diseases, collaborating with top medical institutions to develop innovative treatments.
Anixa Biosciences (NASDAQ: ANIX) announced a presentation of its breast cancer vaccine trial at the ASCO Annual Meeting on June 3-7, 2022. The presentation, led by Dr. George Thomas Budd of Cleveland Clinic, focuses on a Phase 1 trial of an alpha-Lactalbumin vaccine for patients with operable triple-negative breast cancer (TNBC). With TNBC being a significant challenge in oncology, accounting for a high percentage of breast cancer deaths, Anixa’s approach targets proteins unique to this cancer type. The vaccine aims to activate the immune system for early tumor prevention.
On April 6, 2022, Anixa Biosciences (NASDAQ: ANIX) announced that Dr. José Conejo-Garcia will present its ovarian cancer CAR-T technology at The 4th International Workshop on CAR-T on April 29, 2022. He will chair a panel discussing Chimeric Endocrine Receptor T-cell (CER-T) technology for treating ovarian cancer. A Phase 1 clinical trial using this innovative therapy has recently begun at Moffitt Cancer Center. Anixa holds an exclusive worldwide license for this technology.
Anixa Biosciences (NASDAQ: ANIX) has launched a Phase 1 trial for its innovative chimeric endocrine receptor T-cell (CER-T) therapy targeting ovarian cancer at Moffitt Cancer Center. This trial aims to assess the safety and effectiveness of CER-T therapy, which uniquely targets the follicle stimulating hormone receptor (FSHR), exclusively expressed on ovarian cells. With an exclusive license for this technology developed at the Wistar Institute, Anixa partners with leading scientists to enhance treatment options for recurrent, chemo-resistant ovarian cancer, potentially revolutionizing therapy for solid tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the 2022 Virtual Growth Conference hosted by M-Vest from March 28-30, 2022. The presentation will be led by Mike Catelani, the Chief Operating Officer and Chief Financial Officer, who will provide an overview of the company's business and program updates. Anixa focuses on developing cancer treatments and vaccines, including an innovative CAR-T immunotherapy and vaccines targeting triple negative breast cancer and ovarian cancer. For more details, visit www.anixa.com.
Anixa Biosciences (NASDAQ: ANIX) has received a Decision to Grant a patent from the Japanese Patent Office for its ovarian cancer vaccine technology, developed at Cleveland Clinic. This vaccine targets the anti-Müllerian hormone receptor 2 (AMHR2-ED), potentially preventing ovarian cancer, particularly in post-menopausal women. Preclinical studies are ongoing at the National Cancer Institute (NCI), with promising data previously published. Anixa's innovative approach aims to provide a preventative measure against one of the most aggressive cancers, enhancing its therapeutic portfolio.
Anixa Biosciences (NASDAQ: ANIX) announced a significant breakthrough with its partner MolGenie GmbH in developing a new compound that shows greater potency than nirmatrelvir, the primary component of Pfizer's COVID-19 treatment, PAXLOVID. The compound targets the main protease (Mpro) of SARS-CoV-2, which is preserved across various virus variants. Anixa's compounds are undergoing further testing, including cellular assays and animal studies, with potential for improved oral therapies against COVID-19.
Anixa Biosciences (NASDAQ: ANIX) is set to participate in two significant investor conferences: the LifeSci Partners 11th Annual Corporate Access Event on January 5-7, 2022, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Dr. Amit Kumar will address a panel on cancer vaccines on January 7 at 2:00 pm ET. Investors can request 1x1 meetings during both events. Anixa is focused on innovative cancer therapies and COVID-19 treatments, including a vaccine for triple negative breast cancer (TNBC).
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
